Innovation sits at the center of the prescription drugs market, which Polaris Market Research valued at USD 1.27 trillion in 2025, with a projected value of USD 2.36 trillion by 2034 and a CAGR of 7.1% from 2026 to 2034. Beyond demographics and spending, the report points to technological and scientific progress as a key reason the industry continues to expand. This article examines the therapeutic and technology trends that pharmaceutical decision-makers are tracking.

Chronic Disease Burden and Long-Term Treatment

The rising prevalence of diabetes, cancer, cardiovascular diseases, and respiratory disorders is boosting demand for long-term regimens. The report cites the Centers for Disease Control and Prevention in noting that 60% of U.S. adults aged 18–34 have at least one chronic condition, which suggests that demand for chronic disease management is not confined to older patients. Continuous medication is often essential for maintaining patient stability, reducing hospitalizations, and improving survival, which reinforces the role of prescribed therapies across all age groups.

The aging global population adds to this pressure. The World Health Organization projects that the number of people aged 60 and older will increase from 1.1 billion to 1.4 billion by 2030, and older adults typically need more frequent care for arthritis, cardiovascular disorders, and neurodegenerative conditions. By therapy area, the report expects immunology and autoimmune treatments to grow at a CAGR of 8.4% and neurological disorders at 8.1%, while its key takeaways project the Parkinson's segment to grow at 10.4%.

Biologics and Advanced Modalities

Biologics are medicines made from living cells or organisms and are mainly used to treat complex diseases, including cancer and autoimmune disorders. Polaris highlights growing adoption of biologics alongside cell therapies, gene therapies, and RNA-based medicines, which can address disease pathways that traditional therapeutics cannot. A recent example is Casgevy, which received U.S. FDA approval in July 2026 for patients aged 2 years and above with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent β thalassemia.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

https://www.polarismarketresearch.com/industry-analysis/prescription-drugs-market 

This shift is visible in delivery formats as well. The injectable segment is expected to register the highest route-of-administration CAGR of 8.2% from 2026 to 2034, fueled by monoclonal antibodies and insulin analogs, while self-administration devices such as autoinjectors and prefilled syringes extend injectable use into homecare. The homecare segment itself is expected to grow at a CAGR of 7.8%. Oral products still held the largest route share of 52.8% in 2025 because of ease of self-administration and patient compliance.

The Pipeline: GLP-1 and Beyond

The report describes strong momentum in next-generation GLP-1 drugs, driven by chronic disease prevalence and the need for targeted treatment. Players are expanding pipelines in obesity, diabetes, cardiovascular disease, cancer, and orphan diseases. Amgen's MariTide entered phase 3 trials in March 2025 for weight loss and type 2 diabetes, while Eli Lilly's orforglipron and AstraZeneca's elecoglipron are listed among Phase 3 candidates in the obesity and metabolic space. Oral formulations are a particular focus because they simplify administration and may improve compliance, as shown by the January 2025 FDA approval of Vertex's JOURNAVX for moderate-to-severe acute pain.

Other late-stage candidates named in the report include Bristol Myers Squibb's mezigdomide, with its NDA accepted by the FDA, and Mineralys Therapeutics' lorundrostat for treatment-resistant hypertension.

Personalized Medicine and AI

The report identifies the shift toward personalized medicine as a notable opportunity. Treatment selection that draws on genetics, disease characteristics, and individual health profiles can improve efficacy and lower the likelihood of adverse reactions, and this is particularly relevant in oncology. Pharmaceutical firms are developing targeted medications together with diagnostics that predict who is likely to benefit.

Artificial intelligence supports this direction. According to the report, AI algorithms analyze large biological datasets to identify drug candidates, improve trial design through better participant selection, predict individual responses to medication, and help forecast demand, optimize manufacturing, and manage inventory across the supply chain.

Patent Expiry and Competitive Pressure

The main commercial counterweight is patent expiry. When protection ends, new producers introduce lower-priced versions, and the report notes that this can cause a significant drop in sales and compress margins for the original developer. High development costs add further pressure, particularly for smaller firms that lack the resources to fund long research programs. Companies respond through research investment, partnerships, and acquisitions.

Key Players

The industry includes AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Sanofi, and Teva Pharmaceutical Industries. In June 2025, Teva and Fosun Pharma announced a partnership to co-develop TEV-56278, an investigational anti-PD1-IL2 therapy for oncology.

Conclusion

The prescription drugs market is moving toward targeted, technology-enabled treatment. Chronic disease demand provides the base, biologics and gene and cell therapies expand what medicines can do, and the GLP-1 pipeline illustrates how quickly new categories can emerge. At the same time, patent expiry and development costs require disciplined portfolio management. Companies that combine pipeline depth with personalized approaches and efficient manufacturing are well positioned for the forecast period.

More Trending Latest Reports By Polaris Market Research:

sports-betting-market

it-asset-disposition-itad-market

polymer-market

eco-tourism-market

piezoelectric-devices-market

dental-service-organization-market

spinal-implants-market

in-app-purchase-market

data-center-interconnect-market